Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Osteoclasts are important for bone angiogenesis.

Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, Blair HC, Roodman GD.

Blood. 2010 Jan 7;115(1):140-9. doi: 10.1182/blood-2009-08-237628.

3.

The synthetic triterpenoid TP-222 inhibits RANKL stimulation of osteoclastogenesis and matrix metalloproteinase-9 expression.

Fava RA, Elliott S, Raymond L, Mollmark J, Hays E, Honda T, Gribble GW, Sporn MB, Vincenti MP.

J Rheumatol. 2007 May;34(5):1058-68.

PMID:
17361985
4.

Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.

Itoh K, Udagawa N, Matsuzaki K, Takami M, Amano H, Shinki T, Ueno Y, Takahashi N, Suda T.

J Bone Miner Res. 2000 Sep;15(9):1766-75.

5.

Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.

Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T.

Bone. 1999 Nov;25(5):517-23.

PMID:
10574571
6.
7.

Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.

Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC.

Mol Cancer Res. 2010 Apr;8(4):459-70. doi: 10.1158/1541-7786.MCR-09-0445.

8.
9.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

10.

Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.

Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.

Life Sci. 2007 Mar 13;80(14):1311-8.

PMID:
17306833
11.

Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.

Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ.

J Bone Miner Res. 2000 Aug;15(8):1459-66.

13.

Role of IGF-I signaling in regulating osteoclastogenesis.

Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD.

J Bone Miner Res. 2006 Sep;21(9):1350-8.

14.

CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.

Kim JY, Min JY, Baek JM, Ahn SJ, Jun HY, Yoon KH, Choi MK, Lee MS, Oh J.

Bone. 2015 Oct;79:242-51. doi: 10.1016/j.bone.2015.06.011.

PMID:
26103094
15.

Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.

Zhu L, Wei H, Wu Y, Yang S, Xiao L, Zhang J, Peng B.

Int J Biochem Cell Biol. 2012 Jul;44(7):1139-52. doi: 10.1016/j.biocel.2012.04.003.

PMID:
22521613
16.
18.

Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T.

Endocrinology. 2000 Sep;141(9):3478-84.

PMID:
10965921
20.

Effects and mechanism of aromatic aminoketone SY0916 on osteoclastic bone destruction.

Wang L, Peng SY, Liu Y, Li P, Wang WJ.

Acta Pharmacol Sin. 2010 Apr;31(4):470-5. doi: 10.1038/aps.2009.202.

Items per page

Supplemental Content

Support Center